Neflamapimod (VX-745)

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Neflamapimod (VX-745)	Purity：98% min
CAS NO：209410-46-8	Solubility：DMSO : 13.08 mg/mL (29.98 mM)
Molecular Formula：C₁₉H₉Cl₂F₂N₃OS	Package：Package according to customer requirements
Molecular Weight：436.262	Storage：-20℃

Quality control

Remarks

Neflamapimod, also known as VX-745, VRT-031745 and VD-31745, is highly potent and selective p38α inhibitor (IC50 = 10 nM). VX-745 blocks TNFα production in LPS-stimulated HWB in vitro (IC50 = 177 nM). VX-745 displays excellent enzyme activity and selectivity, has a favorable pharmacokinetic profile, and demonstrates good in vivo activity in models of inflammation.

Properties:

Density: 1.55g/cm3

Boiling Point: 578.9ºC at 760mmHg

Flash Point: 303.9ºC

Refractive Index: 1.692

Vapor Pressure: 2.13E-13mmHg at 25°C

p38 MAPK Inhibitors Related Products:

SB203580; Doramapimod; SB-202190; VX-702; Neflamapimod; TAK-715; R1487 HCl; SB239063; Losmapimod; Ralimetinib dimesylate

References

[1]. Duffy JP, et al. The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor. ACS Med Chem Lett. 2011 Jul 28;2(10):758-63.

[2]. Pradal J, et al. Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system. Eur J Pharm Biopharm. 2015 Jun;93:110-7.

[3]. Bagley MC, et al. Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5107-10. Epub 2007 Jul 13.